Compare EXTR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXTR | MIRM |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 7.2B |
| IPO Year | 1999 | 2019 |
| Metric | EXTR | MIRM |
|---|---|---|
| Price | $26.06 | $92.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $33.63 | ★ $157.71 |
| AVG Volume (30 Days) | ★ 1.8M | 559.1K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 616.67 | 74.59 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,283,593,000.00 | $19,138,000.00 |
| Revenue This Year | $9.74 | $37.65 |
| Revenue Next Year | $9.69 | $21.04 |
| P/E Ratio | $223.67 | ★ N/A |
| Revenue Growth | ★ 12.59 | N/A |
| 52 Week Low | $13.48 | $63.23 |
| 52 Week High | $33.73 | $130.00 |
| Indicator | EXTR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 56.52 |
| Support Level | $21.33 | $87.38 |
| Resistance Level | $33.08 | $98.34 |
| Average True Range (ATR) | 1.52 | 4.15 |
| MACD | 0.42 | 0.73 |
| Stochastic Oscillator | 83.95 | 60.16 |
Extreme Networks Inc is an AI-powered cloud-based networking company focused on delivering simple and secure solutions that enable connections among devices, applications, and users. The Company leverages artificial intelligence, analytics, and automation in its products and services, and designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. Its offerings include networking equipment, software subscriptions, related maintenance contracts and the Extreme Platform ONE solution. The Company operates in a single reportable segment focused on the development, marketing, and sale of network infrastructure equipment and related software and subscriptions. The Company generates maximum revenue from the United States.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.